Mar. 19 at 7:42 PM
$WVE (1/2) Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Mar 19, 2026 By Dulan Lokuwithana
...
RBC analyst Leonid Timashev based his analysis on biotech deal speculation in the media. Using M&A commentary posted by four leading publications known for their M&A commentary, namely, The Wall Street Journal, The Financial Times, Bloomberg, and Betaville, Timashev found roughly 85 such reports since 2021.
...
Analysis also looked at the biotechs with the most promising M&A prospects. In addition to Revolution Medicines (RVMD), Ascendis (ASND), and Arrowhead (ARWR), he pointed to Kymera Therapeutics (KYMR), Rhythm Pharmaceuticals (RYTM), Xenon Pharmaceuticals (XENE), Dyne Therapeutics (DYN), and Viridian Therapeutics (DYN) as potential takeover targets.
